Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Eribulin (Primary)
- Indications Salivary gland cancer
- Focus Therapeutic Use
- 20 Feb 2018 Status changed from active, no longer recruiting to completed.
- 28 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018.
- 13 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.